New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced that four abstracts for Arcutis’...

Click to view original post